KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eli Lilly (LLY) Equity Average (2016 - 2026)

Eli Lilly filings provide 18 years of Equity Average readings, the most recent being $28.9 billion for Q1 2026.

  • On a quarterly basis, Equity Average rose 3082.08% to $28.9 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $28.9 billion, a 3082.08% increase, with the full-year FY2025 number at $13.4 billion, up 1067.87% from a year prior.
  • Equity Average hit $28.9 billion in Q1 2026 for Eli Lilly, up from $25.2 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $28.9 billion in Q1 2026 to a low of -$4.3 billion in Q3 2022.
  • Median Equity Average over the past 5 years was -$1.5 billion (2023), compared with a mean of $2.0 billion.
  • Biggest five-year swings in Equity Average: plummeted 311.17% in 2022 and later surged 3176.62% in 2025.
  • Eli Lilly's Equity Average stood at -$2.1 billion in 2022, then rose by 27.27% to -$1.5 billion in 2023, then soared by 46.45% to -$818.8 million in 2024, then surged by 3176.62% to $25.2 billion in 2025, then rose by 14.58% to $28.9 billion in 2026.
  • The last three reported values for Equity Average were $28.9 billion (Q1 2026), $25.2 billion (Q4 2025), and $11.9 billion (Q3 2025) per Business Quant data.